Intended for research use only. Not for use in human, therapeutic, or diagnostic applications.
References
1. Bologa, C. G., Revankar, C. M., Young, S. M., Edwards, B. S., Arterburn, J. B., Kiselyov, A. S., & Prossnitz, E. R. (2006). Virtual and biomolecular screening converge on a selective agonist for GPR30. Nature chemical biology, 2(4), 207-212. 2. Blasko, E., Haskell, C. A., Leung, S., Gualtieri, G., Halks-Miller, M., Mahmoudi, M., & Horuk, R. (2009). Beneficial role of the GPR30 agonist G-1 in an animal model of multiple sclerosis. Journal of neuroimmunology, 214(1), 67-77. 3. Kumar, R., Balhuizen, A., Amisten, S., Lundquist, I., & Salehi, A. (2011). Insulinotropic and antidiabetic effects of 17beta-estradiol and the GPR30 agonist G-1 on human pancreatic islets. Endocrinology, 152(7), 2568-2579.USBio References
No references available